KBR, Inc, Coach Inc Take a Dive on Disappointments

Updated on

Senomyx Inc. (NASDAQ:SNMX), Flexion Therapeutics Inc (NASDAQ:FLXN) and Alamos Gold Inc (NYSE:AGI) are the top three gainers on Wall Street midday today. On the losing end are Northwest Biotherapeutics, Inc (NASDAQ:NWBO), KBR, Inc. (NYSE:KBR) and Coach Inc (NYSE:COH).

Senomyx Hits High Note

Senomyx Inc. (NASDAQ:SNMX) climbed +10.86% by midday today, reaching a two-month high. The biotech company, a new Q1 pick for billionaire investor George Soros, is up +81.82% in 2014 and +331.92% over the past year.

Also starting off this Thursday strong is Flexion Therapeutics Inc (NASDAQ:FLXN). The pharmaceutical firm surged +8.45% today and continues to rally after announcing positive topline results for one of its trials earlier in the week. Thomas Steyer picked up 50,000 FLXN shares in the first quarter of the year, and George Soros 30,000.

The share price of Alamos Gold Inc (NYSE:AGI) increased +7.36% midday – a nice bounce for the firm, which is down -16.82% YTD. Bridgewater Associates head Ray Dalio initiated a position in Alamos in the fourth quarter of 2013 and reduced it slightly during the first quarter of this year.

KBR Continues to Struggle

Northwest Biotherapeutics, Inc (NASDAQ:NWBO) slipped -14.72% midday today. The biotech company, a new Q1 buy for George Soros, is in hot water over claims made regarding results from an ongoing clinical trial. Despite today’s loss, Northwest Biotherapeutics is still up +91.51% in 2014.

The share price of KBR, Inc. (NYSE:KBR) dipped -9.78% as the company continues to disappoint on results and revenues. The global engineering and construction firm said today that it plans to review its business strategy in light of 19 straight periods of declining quarterly revenues. Billionaire investor Ray Dalio initiated a position in KBR in Q1, and David Tepper has been growing his allocation since March 2013.

Taking the final spot on today’s list of losers is Coach Inc (NYSE:COH) The luxury brand fell -8.24%, hitting a new 52-week low as a result of Barclays’ lowered price target from $45 to $48. Richard Chilton bought upwards of 400,000 COH assets during the first quarter of the year, while Steve Mandel unloaded nearly five million (he still holds over 1.5 million).

Leave a Comment